SI
ELVN icon

Sofinnova Investments’s Enliven Therapeutics ELVN Stock Holding History

Sofinnova Investments’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,547
Closed -$660K – 69
2025
Q1 		$660K Sell
33,547
-478
-1% -$10.3K 0.04% 60
2024
Q4 		$766K Buy
+34,025
New +$882K 0.06% 56

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sofinnova Investments's ELVN Position: Q2 2025 in Review

Sofinnova Investments sold out of Enliven Therapeutics (ELVN) in Q2 2025, closing a stake of 33,547 shares — an estimated $660K sold.

Sofinnova Investments first reported a position in ELVN in Q4 2024 and held it in 2 quarters. The position peaked at $766K in Q4 2024. 124 funds tracked by Wall St. Rank hold ELVN as of Q2 2025.

  • Sofinnova Investments reported no remaining Enliven Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sofinnova Investments sold 33,547 Enliven Therapeutics shares in Q2 2025, an estimated $660K.
  • Sofinnova Investments first reported a position in Enliven Therapeutics in Q4 2024 and held it in 2 quarters.
  • Sofinnova Investments's Enliven Therapeutics position peaked at $766K in Q4 2024.
  • 124 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2025.

Based on Sofinnova Investments's 13F filing for Q2 2025, filed 14 Aug 2025.